| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649041112 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg |
01/18/2019 |
17.29 |
593.57 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649041124 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg |
01/18/2019 |
34.58 |
1187.17 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649040130 |
ANUSOl-HC® (Hydrocortisone Cream, USP) 2.5% |
01/18/2019 |
3.88 |
133.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649010302 |
APRISO™ (mesalamine) extended-release capsules 0.375g |
01/18/2019 |
28.89 |
510.31 |
05/01/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
On 6/18/2015 the product had a price decrease from $522 to $379.49. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649020175 |
MOVIPREP® (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate & Ascorbic Acid for Oral Solution) |
01/18/2019 |
5.98 |
105.69 |
09/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649070141 |
OSMOPREP® (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) Tablets |
01/18/2019 |
20.01 |
686.93 |
06/22/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649065103 |
UCERIS® (budesonide) Rectal Foam two 54 ml Canisters 2 mg/actuation |
01/18/2019 |
35.52 |
627.53 |
09/07/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was launched on 12/01/2014. The rights to the product was acquired in 2008 |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649030103 |
XIFAXAN® (rifaximin) 200mg Tablets |
01/18/2019 |
45.49 |
621.28 |
07/24/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649030302 |
XIFAXAN® (rifaximin) 550mg Tablets |
01/18/2019 |
173.41 |
2368.48 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2019 |
65649030303 |
XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10 |
01/18/2019 |
173.41 |
2368.48 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000027 |
Sandoz Inc. |
09/30/2019 |
00781194382 |
AMOX C XR 1000/62.5MG 28TB BT |
07/08/2019 |
15.48 |
171.85 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
09/30/2019 |
00781194339 |
AMOX C XR 1000/62.5MG 40TB BT |
07/08/2019 |
22.11 |
245.49 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
09/30/2019 |
00781214501 |
AMPICILLIN 500MG 100CP BT |
07/08/2019 |
4.66 |
51.78 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
09/30/2019 |
00781214505 |
AMPICILLIN 500MG 500CP BT |
07/08/2019 |
22.74 |
252.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
03/31/2019 |
61314014410 |
BRIMONIDINE TAR 0.15% 10ML |
03/14/2019 |
24.31 |
280.27 |
08/19/2025 |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=53 |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years |
| Rx0000027 |
Sandoz Inc. |
03/31/2019 |
61314014415 |
BRIMONIDINE TAR 0.15% 15ML |
03/14/2019 |
36.47 |
420.43 |
08/19/2025 |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=54 |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years |
| Rx0000027 |
Sandoz Inc. |
03/31/2019 |
61314014405 |
BRIMONIDINE TAR 0.15% 5ML |
03/14/2019 |
12.16 |
140.17 |
08/19/2025 |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=52 |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years |
| Rx0000027 |
Sandoz Inc. |
09/30/2019 |
00781602246 |
CLARITHROMYCIN OS 125MG/5ML 100ML BT |
07/08/2019 |
9.81 |
108.86 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
09/30/2019 |
00781602252 |
CLARITHROMYCIN OS 125MG/5ML 50ML BT |
07/08/2019 |
5.30 |
58.88 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
09/30/2019 |
00781602346 |
CLARITHROMYCIN OS 250MG/5ML 100ML BT |
07/08/2019 |
14.31 |
158.81 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
09/30/2019 |
00781602352 |
CLARITHROMYCIN OS 250MG/5ML 50ML BT |
07/08/2019 |
7.72 |
85.72 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
03/31/2019 |
61314064175 |
NEOMYCIN/POLYMYXIN B/HYDROC OPHT 7.5ML SUSP |
03/14/2019 |
11.82 |
136.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=57 |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. |
| Rx0000027 |
Sandoz Inc. |
03/31/2019 |
61314064610 |
NEOMYCIN/POLYMYXIN B/HYDROC OTIC 10ML LDP SOLN |
03/14/2019 |
8.88 |
83.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=55 |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. |
| Rx0000027 |
Sandoz Inc. |
03/31/2019 |
61314064511 |
NEOMYCIN/POLYMYXIN B/HYDROC OTIC 10ML SUSP |
03/14/2019 |
8.88 |
83.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=56 |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. |
| Rx0000027 |
Sandoz Inc. |
06/30/2019 |
00781300407 |
SOMATROPIN IJ 10MG/1.5ML 1X1CARTRIDGE BOX (OMNITROPE) |
05/01/2019 |
59.55 |
1250.46 |
None |
Single Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=281 |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. |
| Rx0000027 |
Sandoz Inc. |
06/30/2019 |
00781300107 |
SOMATROPIN IJ 5MG/1.5ML 1X1CARTRIDGE BOX (OMNITROPE) |
05/01/2019 |
29.77 |
625.23 |
None |
Single Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=280 |
Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. |
| Rx0000092 |
Santarus, Inc. |
03/31/2019 |
68012025820 |
CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets |
01/18/2019 |
47.48 |
838.74 |
04/30/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504005202 |
HepaGam B 1 mL |
01/01/2019 |
15.84 |
193.85 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
164.59 |
None |
2015 |
150.63 |
None |
None |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504005302 |
HepaGam B 1 mL (NovaPlus) |
01/01/2019 |
15.84 |
193.85 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
164.59 |
None |
2015 |
150.63 |
None |
None |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504005102 |
HepaGam B 5 mL |
01/01/2019 |
69.33 |
848.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
720.33 |
None |
2015 |
659.20 |
None |
None |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504005402 |
HepaGam B 5mL (NovaPlus) |
01/01/2019 |
69.33 |
848.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
720.33 |
None |
2015 |
659.20 |
None |
None |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504012602 |
VARIZIG |
01/01/2019 |
134.19 |
1641.62 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
1306.34 |
None |
2015 |
1185.00 |
None |
None |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504310002 |
WinRho SDF 1000 mcg |
01/01/2019 |
141.06 |
1726.06 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
1437.65 |
None |
2015 |
1182.75 |
None |
None |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504330002 |
WinRho SDF 300 mcg |
01/01/2019 |
42.06 |
514.61 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
428.62 |
None |
2015 |
352.63 |
None |
None |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504300002 |
WinRho SDF 3000 mcg |
01/01/2019 |
423.19 |
5178.18 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
4312.91 |
None |
2015 |
3548.24 |
None |
None |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2019 |
70504350002 |
WinRho SDF 500 mcg |
01/01/2019 |
70.53 |
863.03 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
non-public |
718.82 |
None |
2015 |
591.37 |
None |
None |
| Rx0000086 |
Seattle Genetics, Inc. |
03/31/2019 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
01/01/2019 |
287.00 |
7662.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1) Seattle Genetics does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seattle Genetics limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seattle Genetics to insert only a year for this data field. As a result, Seattle Genetics has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seattle Genetics' patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seattle Genetics did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-U blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
09/30/2019 |
51144005001 |
Brentuximab Vedotin 50 MG Solution Reconstituted 1 EA UD |
07/01/2019 |
299.00 |
7960.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1) Seattle Genetics does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seattle Genetics limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seattle Genetics to insert only a year for this data field. As a result, Seattle Genetics has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seattle Genetics' patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seattle Genetics did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-U blank because they are not applicable to this product. |
| Rx0000121 |
Secura Bio, Inc. |
09/30/2019 |
00078065006 |
Farydak 10 mg |
08/12/2019 |
773.29 |
8913.22 |
06/13/2028 |
Single Source Drug |
728 |
None |
Farydak was acquired from Novartis on March 1, 2019 by Secura Bio, Inc., a newly established company. FDA clinical trial obligations, start-up costs and selling and general costs required to support the product exceed revenues from the product and have resulted in operating losses for the company, necessitating price increases. |
None |
None |
None |
03/01/2019 |
Novartis |
65000000 |
None |
Acquisition price may be higher depending on contingent milestones. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2019 |
00078065006 |
Farydak 10 mg capsule 6x blister pack |
12/02/2019 |
846.76 |
9759.98 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis AG |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
09/30/2019 |
00078065106 |
Farydak 15 mg |
08/12/2019 |
773.29 |
8913.22 |
06/13/2028 |
Single Source Drug |
397 |
None |
Farydak was acquired from Novartis on March 1, 2019 by Secura Bio, Inc., a newly established company. FDA clinical trial obligations, start-up costs and selling and general costs required to support the product exceed revenues from the product and have resulted in operating losses for the company, necessitating price increases. |
None |
None |
None |
03/01/2019 |
Novartis |
65000000 |
None |
Acquisition price may be higher due to contingent milestones. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2019 |
00078065106 |
Farydak 15 mg capsule 6x blister pack |
12/02/2019 |
846.76 |
9759.98 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis AG |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
09/30/2019 |
00078065206 |
Farydak 20 mg |
08/12/2019 |
773.29 |
8913.22 |
06/13/2028 |
Single Source Drug |
935 |
None |
Farydak was acquired from Novartis on March 1, 2019 by Secura Bio, Inc., a newly established company. FDA clinical trial obligations, start-up costs and selling and general costs required to support the product exceed revenues from the product and have resulted in operating losses for the company, necessitating price increases. |
None |
None |
None |
03/01/2019 |
Novartis |
65000000 |
None |
Acquisition price may be higher due to contingent milestones. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2019 |
00078065206 |
Farydak 20 mg capsule 6x blister pack |
12/02/2019 |
846.76 |
9759.98 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis AG |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000004 |
Shionogi Inc. |
03/31/2019 |
59630058090 |
Osphena (ospemifene) 60MG Tablets |
01/01/2019 |
36.61 |
648.00 |
None |
Single Source Drug |
126054 |
None |
The factors contributing to this WAC increase are anticipated increases over 2018 of distribution service fees charged by wholesalers and rebates payable under contracts with government and commercial third party payers. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Osphena was developed by Shionogi. The pricing at launch was $474.00 |
| Rx0000061 |
Shire US |
06/30/2019 |
54092070202 |
Firazyr 30mg/3ml |
04/15/2019 |
324.68 |
11147.49 |
07/15/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Shire is now part of Takeda. Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
54092070203 |
Firazyr 30mg/3ml |
04/15/2019 |
974.05 |
33442.49 |
07/15/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Shire is now part of Takeda. Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
68875010201 |
Gattex Subcutaneous Kit 5 MG |
04/15/2019 |
1143.84 |
39271.88 |
05/01/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/21/2015 |
NPS Pharma |
None |
1 |
None |
31350.00 |
None |
2013 |
24247.00 |
None |
Shire is now part of Takeda. Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
68875010301 |
Gattex Subcutaneous Kit 5 MG |
04/15/2019 |
43.86 |
1505.74 |
05/01/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/21/2015 |
NPS Pharma |
None |
1 |
None |
1202.00 |
None |
2013 |
929.00 |
None |
Shire is now part of Takeda. Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
47783010101 |
Kalbitor Subcutaneous Sol 10 mg/ml |
04/15/2019 |
430.13 |
14767.63 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/22/2016 |
Dyax Corp. |
None |
1 |
None |
11910.00 |
None |
2015 |
11910.00 |
None |
Shire is now part of Takeda. Please note that Patent Expiration Date is not publicly available for Kalbitor. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
68875020502 |
Natpara 100 mcg/dose |
04/15/2019 |
288.85 |
9917.15 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Shire is now part of Takeda. Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Natpara. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
68875020202 |
Natpara 25 mcg/dose |
04/15/2019 |
288.85 |
9917.15 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Shire is now part of Takeda. Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Natpara. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
68875020302 |
Natpara 50 mcg/dose |
04/15/2019 |
288.85 |
9917.15 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Shire is now part of Takeda. Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Natpara. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
68875020402 |
Natpara 75 mcg/dose |
04/15/2019 |
288.85 |
9917.15 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Shire is now part of Takeda. Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Natpara. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000061 |
Shire US |
06/30/2019 |
54092060601 |
Xiidra 5% (60 count 12ml) |
04/15/2019 |
15.21 |
522.21 |
07/25/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Shire is now part of Takeda. Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000149 |
Strongbridge Biopharma plc |
09/30/2019 |
71090000101 |
Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100 |
08/05/2019 |
1565.65 |
18961.81 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/12/2016 |
Taro Pharmaceuticals Industries |
8500000 |
None |
None |
13650.00 |
13650.00 |
2015 |
13650.00 |
None |
None |
| Rx0000001 |
SUN PHARMACEUTICALS |
03/31/2019 |
10631011531 |
Absorica 10mg Capsule |
02/14/2019 |
195.08 |
1063.91 |
09/21/2021 |
Single Source Drug |
4680 |
None |
(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun)
This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products.
For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable. |
| Rx0000001 |
SUN PHARMACEUTICALS |
03/31/2019 |
10631011631 |
Absorica 20mg Capsule |
02/14/2019 |
195.08 |
1063.91 |
09/21/2021 |
Single Source Drug |
23913 |
None |
(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun)
This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products.
For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable. |
| Rx0000001 |
SUN PHARMACEUTICALS |
03/31/2019 |
10631013331 |
Absorica 25mg Capsule |
02/01/2019 |
209.89 |
1143.91 |
09/21/2021 |
Single Source Drug |
8677 |
None |
(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun)
This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products.
For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable. |
| Rx0000001 |
SUN PHARMACEUTICALS |
03/31/2019 |
10631011731 |
Absorica 30mg Capsule |
02/01/2019 |
209.89 |
1143.91 |
09/21/2021 |
Single Source Drug |
89648 |
None |
(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun)
This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products.
For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable. |
| Rx0000001 |
SUN PHARMACEUTICALS |
03/31/2019 |
10631013431 |
Absorica 35mg Capsule |
02/01/2019 |
209.89 |
1143.91 |
09/21/2021 |
Single Source Drug |
10980 |
None |
(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun)
This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products.
For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable. |
| Rx0000001 |
SUN PHARMACEUTICALS |
03/31/2019 |
10631011831 |
Absorica 40mg Capsule |
02/01/2019 |
209.89 |
1143.91 |
09/21/2021 |
Single Source Drug |
126347 |
None |
(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun)
This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products.
For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable. |
| Rx0000001 |
SUN PHARMACEUTICALS |
06/30/2019 |
62756052940 |
Desmopressin Acetate 40mcg/10ml Solution for Injection |
04/03/2019 |
401.20 |
594.20 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
Sun's Desmopressin Acetate is being re-launched to the market after a hiatus.This product is priced to reflect a discount off of the current price of the Reference Drug listed by the FDA and to be competitively priced in the market. |
None |
No change or improvement have been made for this product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Sun Pharma did not acquire the drug. 2)This product was re-launched in April 2019, and there were no reported sales for the past years prior to April 2019. Therefore, the Volume Sales Units for the year 2018 were zero 3) This report includes confidential, trade secret information of Sun Pharmaceutical Industries, Inc. (Sun) that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772012101 |
Oxtellar XR, 150mg Capsule, 100CT |
01/01/2019 |
49.05 |
662.21 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772012201 |
Oxtellar XR, 300mg Capsule, 100CT |
01/01/2019 |
68.15 |
919.99 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772012301 |
Oxtellar XR, 600mg Capsule, 100CT |
01/01/2019 |
124.77 |
1684.42 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772010301 |
Trokendi XR, 100mg Capsule, 100CT |
01/01/2019 |
182.75 |
2467.18 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772010330 |
Trokendi XR, 100mg Capsule, 30 CT |
01/01/2019 |
54.83 |
740.15 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772010401 |
Trokendi XR, 200mg Capsule, 100CT |
01/01/2019 |
249.99 |
3374.92 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772010430 |
Trokendi XR, 200mg Capsule, 30 CT |
01/01/2019 |
75.00 |
1012.48 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772010101 |
Trokendi XR, 25mg Capsule, 100 CT |
01/01/2019 |
70.81 |
955.95 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772010130 |
Trokendi XR, 25mg Capsule, 30 CT |
01/01/2019 |
21.24 |
286.79 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772010201 |
Trokendi XR, 50mg Capsule, 100CT |
01/01/2019 |
92.24 |
1245.23 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2019 |
17772010230 |
Trokendi XR, 50mg Capsule, 30 CT |
01/01/2019 |
27.67 |
373.56 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |